Omar Amirana, M.D. Managing Director | Allied Minds, Inc.
Omar is the Managing Director, Life Sciences at Allied Minds. Prior to joining Allied Minds, he served as a Partner at Oxford Bioscience Partners, a Boston-based life sciences venture capital firm with ~$1B under management. He is currently on the board of Cardiofocus (catheter ablation of AF) and Cambridge Endoscopic Devices (articulating laparoscopic surgical tools), and served on the boards of Coherex (catheter closure of LAA and PFO), Smartpill (GI diagnostic capsule technology), Mitralign (percutaneous heart valve repair), NFocus (catheter based aneurysm therapy), and Flowmedica (targeted renal therapy). He was the co-founder of two medical device companies, Cardima and Resolution Medical, and was the VP of Marketing of MedicaLogic/Medscape, a leading EMR/HCIT company. He also served as VP of Business Development at St Jude Medical (STJ, $5.2B in revenue) focused on cardiology and vascular intervention. As the co-founder of Propel Careers, he is passionate about helping aspiring entrepreneurs in life sciences. Omar earned a B.S. in Mechanical Engineering from Tufts University and an M.D. from Eastern Virginia Medical School.
Michelle L. Basil Chair, Life Sciences Group | Nutter McClennen & Fish LLP
Michelle L. Basil is a partner in the Business Department of Nutter, a member of the firm’s Emerging Companies practice group and chair of the Life Sciences practice group. Michelle’s practice focuses on corporate and securities law, including angel and venture capital transactions, public securities offerings, mergers and acquisitions, strategic partnerships and collaborations, licensing, distribution transactions and corporate governance, and equity compensation matters. Michelle represents clients in a broad range of industries, including public and private life sciences, high technology and financial services companies. Michelle serves as outside general counsel to companies in biotechnology, medical devices, diagnostics, and health care services. Michelle received her B.A. and J.D. from the University of California, Berkeley. Michelle is a member of or participates at Boston Harbor Angels, M2D2, MTTC, Launchpad Venture Group, MassBio and MassMEDIC.
Alexis Borisy Partner | Third Rock Ventures, LLC
Alexis Borisy is a successful biotechnology entrepreneur with 20 years of experience building and operating innovative science based organizations. Alexis joined Third Rock Ventures in 2009 as an Entrepreneur-in-Residence and was named Partner in 2010. Alexis focuses on the formation, development and strategy of new companies, including Warp Drive Bio for which he serves as CEO. Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its CEO, and bringing the company public on the NASDAQ in an IPO. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the MIT Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar. Alexis’s undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis serves on the Board of the Biotechnology Industry Organization, is an Overseer at the Boston Museum of Science, and is the Chairman of Forma Therapeutics.
David H. Donabedian, Ph.D. Senior Vice President | Locust Walk Partners, LLC
David brings to Locust Walk over a decade of operating, start up and consulting experience in the life sciences industry. He most recently served as Vice President of Business Development at GSK’s Centre of Excellence for External Drug Discovery (ceedd). In this role, he was accountable for setting the ceedd’s new deal portfolio strategy and composition and working closely with GSK worldwide business development to establish new alliances. Prior to GSK, David built a successful consultancy practice providing corporate strategy and business development services to emerging biotechnology companies. David’s previous senior level positions include COO, SVP and VP of Business Development for BioChemics and Surface Logix. In both roles, David was instrumental in deal portfolio strategy, as well as developing and executing new alliances. David also worked as a Senior Manager in Accenture’s health care practice leading consulting engagements for a number of big pharma clients, including the post-merger integration between GlaxoWellcome and SmithKline Beecham. David began his career as a research scientist with Dow Chemical and Boston Scientific. David holds a Ph.D. in Polymer Chemistry from the University of Massachusetts, and an M.B.A from the University of North Carolina’s Kenan Flagler Business School.
Laurie Halloran Chief Executive Officer | Halloran Consulting Group
Throughout her 24 years in the pharmaceutical and biotechnology industry, Laurie Halloran has demonstrated her commitment to improving the organizational effectiveness of clinical research programs. Optimizing the execution of clinical research programs requires a depth and breadth of experience not commonly found in the industry today. Laurie’s major accomplishments reflect her contributions and expertise throughout the multiple phases of the drug development process. Some of her accomplishments include leading clinical development in several biopharmaceutical companies from IND through late stage clinical trials, and reorganizing dozens of biopharma clinical research departments to optimize organizational efficiency. Laurie was recognized in 2010 by Pharmavoice as one of the 100 most inspiring individuals. She is well known as an industry expert – speaking, publishing and training throughout the world on best practices. She obtained her B.S.N. from Russell Sage College and her M.S. from Lesley University and is on the faculty of Boston University Medical School.
Jeremy Halpern Partner, Emerging Companies Group | Nutter McClennen & Fish LLP
Jeremy’s practice focuses on private equity, venture capital, and angel financing transactions, mergers and acquisitions, equity and entrepreneurial compensation matters, and general start-up support. As a former entrepreneur, Jeremy spends a large portion of his time on behalf of the firm, connecting with and supporting the entrepreneurial ecosystem in New England. Concurrently, Jeremy serves on the Board of The Capital Network and on the Board of Directors of MassVentures, the venture capital arm of the Commonwealth. Jeremy is also a Professor of Entrepreneurial Leadership at Tufts University, a Connector in the Boston World Partnership, and a proud co-founder of BostonIDEA (helping the entrepreneurship community in the Innovation District build relationships), and of MassApps (a mobile application development competition leveraging public data). Previously, Jeremy was the Co-Founder and Executive Vice President of Business Development for MobileTek Corporation, a developer of PC based applications enabling smarter mobility for consumer mobile devices. Prior to that, Jeremy ran a strategic consulting firm and practiced corporate law with other national law firms in Boston and Los Angeles. Jeremy is a member of or participates at Launchpad Venture Group, Boston Harbor Angels, Golden Seeds, NE Angels, MassChallenge, Web Innovators Group, MassTLC and MobileMondays.
Robert S. Langer, Sc.D. David H. Koch Institute Professor | Massachusetts Institute of Technology
Robert S. Langer is the David H. Koch Institute Professor (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written more than 1,180 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995-2002 and as its Chairman from 1999-2002. He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.
Dr. Langer has received over 220 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world’s largest technology prize and the 2012 Priestley Medal, the highest award of the American Chemical Society. He is the also the only engineer to receive the Gairdner Foundation International Award. He was elected to the Institute of Medicine of the National Academy of Sciences, the National Academy of Engineering and to the National Academy of Sciences. Dr. Langer has received honorary doctorates from Harvard University, the Mt. Sinai School of Medicine, Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), Rensselaer Polytechnic Institute, Willamette University, the University of Liverpool (England), Bates College, the University of Nottingham (England), Albany Medical College, Pennsylvania State University, Northwestern University, Uppsala University (Sweden) and the University of California – San Francisco Medal.
Paul LaViolette Partner | SV Life Sciences
Paul brings over 28 years of global medical technology marketing and general management experience. Paul was most recently Chief Operating Officer at Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he also served as Group President, President-Cardiology and President-International. Paul integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. Paul previously held marketing and general management positions at CR Bard, and other roles at Kendall (Covidien). He served on the boards of Urologix, Percutaneous Valve Technologies and Advamed and currently serves on the boards of Cameron Health, CardioFocus, Conceptus, CardioKinetix, CSA Medical, DC Devices, Direct Flow Medical, Thoratec, TransEnterix, TranS1, ValenTx and Medical Device Manufacturers Association (MDMA). Paul received his BA in Psychology from Fairfield University and his MBA from Boston College.
Bill McPhee Angel Investor; Managing Director | Praxis Advisors LLC
Bill has over 25 years of experience in venture capital, transactions, and strategy and operations consulting. He is currently Managing Director at Praxis Advisors, a partnership of four senior executives that works with managers, directors and investors of early stage medtech businesses to monetize life science technology. Bill was previously Founder and Managing General Partner at Mi3 Venture Partners, where he created strategy for an early stage fund focused on bioengineering. Prior to that, he was Director of Outsourced Business Development Services for Health Advances LLC, a life science strategy consulting boutique. Bill was also Founder and Managing Director at management consulting firms Kenilworth Advisors and Lucas, McPhee & Company. His most recent projects include a photon-based anti-infection therapy, a new generation heart pump, and a portfolio of technologies/products to treat glaucoma.
Leslie J. Williams, BS, RN, MBA Chief Executive Officer | ImmusanT, Inc.
Leslie Williams has more than 20 years of industry experience in healthcare, management, commercial product development and marketing. In 2010 she founded ImmusanT, Inc. which subsequently acquired the assets of Melbourne, Australia based Nexpep. Ms. Williams serves as Director, President & CEO of ImmusanT. Prior to that, she was President & CEO of Ventaira Pharmaceuticals and under her leadership the company became a significant player in the pulmonary drug-delivery market. While President and CEO of Ventaira Pharmaceuticals, she was recognized as one of the top 100 leaders in life sciences by PharmaVOICE magazine. Prior to Ventaira, Ms. Williams was director of marketing for INO Therapeutics, Inc. (acquired by Ikaria Holdings in 2007), where she played a significant role in the NDA submission for INOmax (nitric oxide) for inhalation, a drug for treating pulmonary hypertension. Ms. Williams’ prior pharmaceutical industry experience includes commercial positions at Merck and GlaxoSmithKline, and drug-delivery and -monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.). She has been a venture partner at Battelle Ventures. She currently serves on the Boards of Hepregen Corporation, CDI Bioscience and The Capital Network (TCN) and is on the Editorial Advisory Board of Life Science Leader. She serves as a mentor in the Boston University Kindle Program as well as Propel Careers. Ms. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree with honors in nursing from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa.
Susan R. Windham-Bannister, Ph.D. President and CEO | Massachusetts Life Sciences Center
Dr. Susan Windham-Bannister is the first President and CEO of the Massachusetts Life Sciences Center (MLSC), a quasi-public organization charged with administering the 10-year $1 billion Life Sciences Initiative enacted by the Massachusetts Legislature in June 2008. The MLSC is the hub for all sectors of the Commonwealth’s life sciences community – biotechnology, pharmaceuticals, medical devices, medical diagnostics and bioinformatics. Before assuming her role at the MLSC, Dr. Windham-Bannister co-founded Abt Bio-Pharma Solutions (ABS), a boutique consulting firm serving life sciences companies. Within ABS, Dr. Windham-Bannister managed the Commercial Strategy Group. Dr. Windham-Bannister has co-authored two books: Competitive Strategy for Health Care Organizations, and Medicaid and Other Experiments in State Health Policy. She also has written numerous articles on competition in today’s health care marketplace. Dr. Windham-Bannister received a B.A. from Wellesley College, a doctorate in health policy and management from the Florence Heller School at Brandeis University, and a Doctor of Science from Worcester Polytechnic Institute in 2012 (honoris causa). She completed her doctoral work under a fellowship from the Ford Foundation and was also a post-doctoral fellow at Harvard University’s John F. Kennedy School.
Acceleration2016 December 6, 2016 | 3:00-7:00 PM Boston, Massachusetts